Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.
Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here are three value stocks with poor fundamentals and some alternatives you should consider instead.
Crown Holdings (CCK)
Forward P/E Ratio: 13.9x
Formerly Crown Cork & Seal, Crown Holdings (NYSE:CCK) produces packaging products for consumer marketing companies, including food, beverage, household, and industrial products.
Why Are We Wary of CCK?
- The company has faced growth challenges as its 1.9% annual revenue increases over the last five years fell short of other industrials companies
- Gross margin of 20.3% is below its competitors, leaving less money to invest in areas like marketing and R&D
- Earnings growth over the last five years fell short of the peer group average as its EPS only increased by 2.3% annually
Crown Holdings’s stock price of $118.44 implies a valuation ratio of 13.9x forward P/E. Dive into our free research report to see why there are better opportunities than CCK.
BioMarin Pharmaceutical (BMRN)
Forward P/E Ratio: 10.7x
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Do We Think Twice About BMRN?
- Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 5.5 percentage points
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
- High net-debt-to-EBITDA ratio of 6× could force the company to raise capital on unfavorable terms if market conditions deteriorate
BioMarin Pharmaceutical is trading at $64.77 per share, or 10.7x forward P/E. If you’re considering BMRN for your portfolio, see our FREE research report to learn more.
Walker & Dunlop (WD)
Forward P/B Ratio: 0.8x
Originating as a small mortgage banking firm during the Great Depression in 1937, Walker & Dunlop (NYSE:WD) provides commercial real estate financing, property sales, appraisal, and investment management services with a focus on multifamily properties.
Why Should You Sell WD?
- Annual net interest income declines of 41.6% for the past five years show its loan book struggled during this cycle
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 13.7% annually while its revenue grew
- Tangible book value per share tumbled by 8.5% annually over the last five years, showing banking sector trends are working against it during this cycle
At $41.35 per share, Walker & Dunlop trades at 0.8x forward P/B. Dive into our free research report to see why there are better opportunities than WD.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.